WilmerHale Advises Nabriva Therapeutics in Term Loan

WilmerHale Advises Nabriva Therapeutics in Term Loan

Firm News

Related Solutions

We guide clients through today’s ever-changing debt markets, representing them in a broad variety of debt deals that range from complex financial structures to traditional loan transactions.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

WilmerHale advised Nabriva Therapeutics plc (NASDAQ:NBRVF), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, in an up to $75 million term loan with Hercules Capital, Inc. (NYSE:HTGC), $25 million of which was funded on the day of closing.

Brian Johnson and Jamie Class led the WilmerHale team representing Nabriva in this transaction, which also included Ellie Guadiana on credit matters and Scott Lunin and Alex Dzioba on corporate matters. 

Nabriva's announcement regarding the financing can be found at www.nabriva.com.

 

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel